Bimekizumab Clinical Efficacy Up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies

Bimzelx (bimekizumab-bkzx) - UCB

Humira (adalimumab) - AbbVie

Philip Mease; Laure Gossec; Hideto Kameda; David Nicholls; Proton Rahman; Barbara Ink; Rajan Bajracharya; Patrick Healy; Laura Coates

May 7, 2026